91419-49-7

Basic information

• Product Name: 1-N-BOC-PIPERIDINE-3-CARBOXAMIDE
• Synonyms: 3-CARBAMOYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-N-BOC-PIPERIDINE-3-CARBOXAMIDE;1-N-Boc-3-piperidinecarboxamide;1-TERT-BUTOXYCARBONYL-3-METHYLAMINOPIPERIDINE;1-Boc-piperidine-3-carboxamide;1-Piperidinecarboxylic acid, 3-(aminocarbonyl)-, 1,1-dimethylethyl ester;1-N-BOC-3-CARBAMOYLPIPERIDINE;tert-butyl 3-(aminocarbonyl)piperidine-1-carboxylate
• CAS NO: 91419-49-7
• Molecular Formula: C₁₁H₂₀N₂O₃
• Molecular Weight: 228.29
• Mol File: 91419-49-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 174.0 to 178.0 °C
• Boiling Point: 384.4 °C at 760 mmHg
• Flash Point: 186.3 °C
• Appearance: /
• Density: 1.123 g/cm³
• Vapor Pressure: 4.1E-06mmHg at 25°C
• Refractive Index: 1.498
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: 16.41±0.20(Predicted)
• CAS DataBase Reference: 1-N-BOC-PIPERIDINE-3-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-PIPERIDINE-3-CARBOXAMIDE(91419-49-7)
• EPA Substance Registry System: 1-N-BOC-PIPERIDINE-3-CARBOXAMIDE(91419-49-7)

Safety Data

• Statements: 22
• Safety Statements: 37
• Hazardous Substances Data: 91419-49-7(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Synthesis Reference(s)

Synthetic Communications, 20, p. 1203, 1990 DOI: 10.1080/00397919008052828

InChI:InChI=1/C11H20N2O3/c1-11(2,3)16-10(15)13-6-4-5-8(7-13)9(12)14/h8H,4-7H2,1-3H3,(H2,12,14)

Upstream product

• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 4138-26-5 nipecotamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 498-95-3 nipecotic acid 

Downstream Products

• 1271809-14-3 C₁₅H₁₈N₄OS 
• 1271809-12-1 C₂₀H₂₆N₄O₃S 
• 1271802-74-4 1-(2-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)thiazol-5-yl)-3-phenylurea 
• 1271808-87-7 C₂₀H₂₆N₄O₃S 
• 1192248-02-4 tert-Butyl 3-[4-(ethoxycarbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate 
• 1271802-37-9 1-(2-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)thiazol-4-yl)-3-phenylurea 
• 91419-64-6 5-<1-(tert-butoxycarbonyl)-3-piperidyl>-1H-tetrazole 
• 162167-97-7 tert-butyl 3-(aminomethyl)piperidine-1-carboxylate 
• 940868-22-4 tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)piperidine-1-carboxylate 
• 479080-28-9 tert-butyl 3-[amino(hydroxyimino)methyl]piperidine-1-carboxylate 
• 274682-80-3 3-thiocarbamoylpiperidine-1-carboxylic acid tert-butyl ester 
• 91419-53-3 (+/-)-2-N-tert-butoxycabonylpiperidine-3-carbonitrile 
• 479080-28-9 3-(N-hydroxycarbamimidoyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

General Ser/Thr Kinases Pharmacophore Approach for Selective Kinase Inhibitors Search as Exemplified by Design of Potent and Selective Aurora A Inhibitors

A general pharmachophore model for various types of Ser/Thr kinases was developed. Search for the molecules fitting to this pharmacophore among ASINEX proprietary library revealed a number of compounds, which were tested and appeared to possess some activity against several Ser/Thr kinases such as Aurora A, Aurora B and Haspin. The possibility of performing the fine-tuning of the general Ser/Thr pharmacophore to desired types of kinase to get active and selective inhibitors was exemplified by Aurora A kinase. As a result, several hits in 3–5?nm range of activity against Aurora A kinase with rather good selectivity and ADME properties were obtained.

BRUTON'S TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors

The present invention relates to new compounds which are Oxadiazole derivatives of formula (I) wherein B, P, Q, W, R1 and R2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or peripheral nervous system disorders as well as other disorders modulated by mGluR5 receptors.(I).